Participant flow

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer · Source last updated 2019-04-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles

   id

   FG000

   title

   Carbo/Taxol

2. description

   Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Gemcitabine 800 mg/m2/dIV on days 1 and 8 x 8 cycles

   id

   FG001

   title

   Carbo/Taxol/Gemcitabine

3. description

   Carboplatin AUC 5 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 8 cycles plus Doxil 30 mg/m2 IV every other cycle on day 1 x 8 cycles

   id

   FG002

   title

   Carbo/Taxol/Doxil

4. description

   Topotecan 1.25 mg/m2/dIV days 1-3 plus Carboplatin AUC 5 IV on day 3 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles

   id

   FG003

   title

   Carbo/Topotecan - Carbo/Taxol

5. description

   Gemcitabine 1000 mg/m2/dIV on days 1 and 8 plus Carboplatin AUC 6 IV on day 8 plus x 4 cycles followed by Carboplatin AUC 6 IV on day 1 plus Paclitaxel 175 mg/m2 IV on day 1 x 4 cycles

   id

   FG004

   title

   Carbo/Gemcitabine - Carbo/Taxol

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         864

      2. group Id

         FG001

         num Subjects

         864

      3. group Id

         FG002

         num Subjects

         862

      4. group Id

         FG003

         num Subjects

         861

      5. group Id

         FG004

         num Subjects

         861

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         862

      2. group Id

         FG001

         num Subjects

         860

      3. group Id

         FG002

         num Subjects

         854

      4. group Id

         FG003

         num Subjects

         846

      5. group Id

         FG004

         num Subjects

         851

      type

      Initiated Treatment

   3. achievements

      1. group Id

         FG000

         num Subjects

         864

      2. group Id

         FG001

         num Subjects

         864

      3. group Id

         FG002

         num Subjects

         862

      4. group Id

         FG003

         num Subjects

         861

      5. group Id

         FG004

         num Subjects

         861

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         0

      5. group Id

         FG004

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

This study involved patients enrolled from two cooperative groups with the plan to combine data. 3882 patients were enrolled from one cooperative group and 430 from the other. This report includes those patients from both groups.

recruitment Details

Received began 1/29/2001 and ended 1/28/2003. This was an interventional trial involving patients enrolled from the United States (US), Canada, United Kingdom (UK), Italy, Australia, and New Zealand.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice